摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

反式-3-(boc-氨基)-4-羟基哌啶 | 859854-68-5

中文名称
反式-3-(boc-氨基)-4-羟基哌啶
中文别名
——
英文名称
(+/-)-tert-butyl (trans-4-hydroxypiperidin-3-yl)carbamate
英文别名
tert-butyl N-[(3S,4S)-4-hydroxypiperidin-3-yl]carbamate
反式-3-(boc-氨基)-4-羟基哌啶化学式
CAS
859854-68-5
化学式
C10H20N2O3
mdl
——
分子量
216.28
InChiKey
REUNVCLBHFFYFH-YUMQZZPRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    70.6
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    反式-3-(boc-氨基)-4-羟基哌啶 、 2-溴-5-碘咪唑并[2,1-B][1,3,4]噻二唑 在 三乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 生成
    参考文献:
    名称:
    INE963 的发现和临床前药理学,一种强效和快速作用的血期抗疟药,对非复杂性疟疾具有高耐药性和单剂量治愈潜力
    摘要:
    使用血液分期恶性疟原虫( Pf ) 生长抑制试验,通过基于表型的高通量筛选鉴定了一系列 5-芳基-2-氨基-咪唑并噻二唑( ITD ) 衍生物。一项主要优化计划侧重于提高抗疟原虫效力、对人类激酶的选择性以及吸收、分布、代谢、排泄和毒性特性以及扩展的药理学特征,最终鉴定出INE963 ( 1 ),证明了对Pf 3D7的有效细胞活性。 EC 50 = 0.006 μM)并达到“青蒿素样”杀灭动力学在体外,寄生虫清除时间<24小时。单剂量 30 mg/kg 在Pf人源化严重联合免疫缺陷小鼠模型中完全治愈。INE963 ( 1 ) 在药物选择研究中还表现出很高的抗药性屏障和跨物种的长半衰期 ( T 1/2 )。这些特性表明INE963 ( 1 )具有巨大的潜力,可以通过短剂量方案为简单的疟疾提供治愈性疗法。由于这些原因,INE963 ( 1 ) 通过 GLP 毒理学研究取得了进展,目前正在进行 Ph1
    DOI:
    10.1021/acs.jmedchem.1c01995
点击查看最新优质反应信息

文献信息

  • 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS
    申请人:Galxo Group Limited
    公开号:US20150175600A1
    公开(公告)日:2015-06-25
    Compounds of formula (I): wherein; R 1 is hydrogen or C 1-6 alkyl; R 2 is hydrogen, C 1-6 alkyl, perhalomethylC 0-5 alkyl-O—, or C 1-6 alkoxy; R 3 is hydrogen, C 1-6 alkyl, or C 1-6 alkoxyC 1-6 alkyl; R 4 is hydrogen, C 1-6 alkyl, perhalomethylC 1-6 alkyl; or unsubstituted C 3-6 cycloalkylC 1-6 alkyl; A is C—R 5 or N; B is C—R 6 or N; D is C—R 7 or N; with the proviso that at least one of A, B, and D, is N; R 5 is hydrogen or C 1-6 alkyl; R 6 is hydrogen or C 1-6 alkyl; R 7 is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, or hydroxy; R 8 is hydrogen or C 1-6 alkyl, with the proviso that one of R 4 and R 8 is hydrogen; R 9 is hydrogen or hydroxy; R 10 is hydrogen or C 1-6 alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    式(I)的化合物:其中;R1为氢或C1-6烷基;R2为氢、C1-6烷基、全氟甲基C0-5烷基-O—、或C1-6烷氧基;R3为氢、C1-6烷基,或C1-6烷氧基C1-6烷基;R4为氢、C1-6烷基、全氟甲基C1-6烷基;或未取代的C3-6环烷基C1-6烷基;A为C—R5或N;B为C—R6或N;D为C—R7或N;但要求A、B、和D中至少有一个为N;R5为氢或C1-6烷基;R6为氢或C1-6烷基;R7为氢、C1-6烷基、C1-6烷氧基,或羟基;R8为氢或C1-6烷基,但要求R4和R8中的一个为氢;R9为氢或羟基;R10为氢或C1-6烷基;其盐为PAD4抑制剂,可能在治疗各种疾病中有用,例如类风湿性关节炎、血管炎、系统性红斑狼疮、溃疡性结肠炎、癌症、囊性纤维化、哮喘、皮肤红斑性狼疮和牛皮癣。
  • CHEMICAL COMPOUNDS 251
    申请人:Dakin Leslie
    公开号:US20110218182A1
    公开(公告)日:2011-09-08
    The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
    该发明涉及化学式(I)的化合物及其盐。在某些实施例中,该发明涉及PIM-1和/或PIM-2以及/或PIM-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中,该发明涉及包含本文披露的化合物的药物组合物,以及它们在预防和治疗PIM激酶相关疾病和疾病,特别是癌症中的用途。
  • CDK Modulators
    申请人:Bahceci Suleyman
    公开号:US20110201599A1
    公开(公告)日:2011-08-18
    A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof.
    根据公式I的化合物:或其药学上可接受的盐,其中R1,R3,A,B和D如规范中定义;其制药组合物以及使用方法。
  • Chemical Compounds 251
    申请人:AstraZeneca AB
    公开号:US20150051185A1
    公开(公告)日:2015-02-19
    The invention relates to chemical compounds of formula I, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
    本发明涉及公式I的化合物及其盐。在某些实施例中,本发明涉及PIM-1和/或PIM-2,以及/或PIM-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中,本发明涉及包含本文所披露的化合物的制药组合物,以及它们在预防和治疗PIM激酶相关的疾病和状况,尤其是癌症方面的应用。
  • 2 - (AZAINDOL-2-YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS
    申请人:GLAXO GROUP LIMITED
    公开号:US20160009716A1
    公开(公告)日:2016-01-14
    Compounds of formula (I) wherein; R 1 is hydrogen or C 1-6 alkyl; R 2 is hydrogen, C 1-6 alkyl, perhalomethylC 0-5 alkyl-O—, or C 1-6 alkoxy; R 3 is hydrogen, C 1-6 alkyl, or C 1-6 alkoxyC 1-6 alkyl; R 4 is hydrogen, C 1-6 alkyl, perhalomethylC 1-6 alkyl; or unsubstituted C 3-6 cycloalkylC 1-6 alkyl; A is C—R 5 or N; B is C—R 6 or N; D is C—R 7 or N; with the proviso that at least one of A, B, and D, is N; R 5 is hydrogen or C 1-6 alkyl; R 6 is hydrogen or C 1-6 alkyl; R 7 is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, or hydroxy; R 8 is hydrogen or C 1-6 alkyl, with the proviso that one of R 4 and R 8 is hydrogen; R 9 is hydrogen or hydroxy; Rio is hydrogen or C 1-6 alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    化合物的公式(I)其中; R1是氢或C1-6烷基; R2是氢,C1-6烷基,全卤甲基C0-5烷基-O-,或C1-6烷氧基; R3是氢,C1-6烷基或C1-6烷氧基C1-6烷基; R4是氢,C1-6烷基,全卤甲基C1-6烷基; 或未取代的C3-6环烷基C1-6烷基; A是C-R5或N; B是C-R6或N; D是C-R7或N; 前提是A,B和D中至少有一个是N; R5是氢或C1-6烷基; R6是氢或C1-6烷基; R7是氢,C1-6烷基,C1-6烷氧基或羟基; R8是氢或C1-6烷基,前提是R4和R8中的一个是氢; R9是氢或羟基; Rio是氢或C1-6烷基; 其盐是PAD4抑制剂,可能在治疗各种疾病方面有用,例如类风湿性关节炎,血管炎,系统性红斑狼疮,溃疡性结肠炎,癌症,囊性纤维化,哮喘,皮肤红斑性狼疮和银屑病。
查看更多